EYPT EyePoint Pharmaceuticals Inc

$EYPT Alright everyone, I am still around but not posting. Here is my latest and you know it. 1. DURAVYU is a fundamentally different treatment concept. EyePoint uses a bioerodible sustained-release insert containing vorolanib. Rather than extending the half-life of an injected antibody, the goal is to maintain continuous VEGF-pathway suppression inside the eye for roughly six months. Kodiak’s Zenkuda remains an intravitreal biologic injection whose ABC technology extends ocular exposure. That distinction could matter commercially. If DURAVYU ultimately delivers reliable six-month control, the physician is essentially placing a sustained drug depot rather than trying to determine how far an individual patient can be stretched between injections. Continued below

$EYPT If LUCIA meets its primary non-inferiority endpoint cleanly (with strong secondaries on durability, treatment burden, anatomy, and safety), the package would resemble the Apellis model: one clear positive pivotal trial + a second trial that missed its primary but contributes supportive data (ad hoc analyses, secondaries, and an explanation for the miss).

$EYPT If Lucia is successful, the duration is 33% longer before retreat compared to KOD. The technology and delivery system is superior, KOD is antiquated gel release not more precisely engineered dissolvable inserts. Eypt is actually superior both in terms of duration and technology. So f this. If they csn go to 100.00 so shall we. Plus we have the in house MFG facilities

$EYPT 9 outlier patients is not going to bring down this company . Duravyu is solid and I’m confident Lucia will deliver . We will be back 👊

$EYPT From Regillo’s presentation this week at Retina society. 0.5% ≥15-letter loss in the LUGANO aflibercept arm versus roughly 3–6% historically is suspiciously clean. If LUCIA somehow gets another suspiciously spotless Eylea arm, we’re going to need to meet whoever’s spinning that randomization wheel.

$EYPT Today’s Schedule G is a badly needed confirmation that mega shareholders still have confidence in EYPT and its potential for success. Cheers and glta longs.

$EYPT $EYPT The deeper LUGANO gets analyzed, the stronger the DURAVYU story looks. Different audits of the data—outlier analysis, median BCVA, supplement-free patients, anatomy, rescue response, GA and safety—all keep pointing the same direction: the headline miss looks increasingly like an anomalous statistical outcome, not a failed drug. LUCIA is still binary, but the totality of evidence makes success look more likely than not to me. At these prices, I wouldn’t want to be short. This has the feel of a phoenix rising.

$EYPT Just wait until the clinical trials go well Eypt will skyrocket at least back to where it was prior to the dip 💨 🚀 🌕

$EYPT This is no more a matter of profit for me i want all those shorts whobare suppressing it fucked !

$EYPT looks like consolidation is wrapping up. Anytime SP positive on red XBI day is a win .

$EYPT yesterday I sold 5,000 shares out of 15,000 to make some profit. If this falls to around the $3.10 mark again I will be buying the 5,000 shares I sold back and an additional 5,000 shares. I believe with this price action and looking back on charts that this has been pushed down for re entry points for insiders. I think good news is coming and they know it.

$EYPT noticed they removed the latest investor presentation updated in August . Not sure if this is good or bad or neutral . But definitely points to tomorrow as the big day for the Lucia data drop.

$EYPT Kodiak, Ocular, and the broader biotech sector (XBI) had the same sell off pattern today. Not sure wtf is going on. I’m convinced lugano was a total fluke heavily influenced by that unusually favorable control arm. A difference of just two or three patients could have changed the outcome. If lucia even barely hits and the entire narrative gets rewritten. Having said that, EYPT has been really freaking quiet the past couple of weeks post EuRetina and AAO. While OCUL is swinging its dick all over social media. Will find out in a few weeks or less…

$EYPT if we assume last patient last visit was early september and data base lick and cleaning take 4 - 6 weeks, data should arrive between next week and the fist week of november.... also assume, all eyes are on this data and they will be double and triple checking to make sure no stine is unturned... so... i think data is coming 2 weeks from Monday

$EYPT when people post things on here like "Case closed" "end of story" in a vote of confidence....yet they are down 71% on this investment. Realize they are doing so with HOPE not facts...because the only fact here that matters is that EYPT missed it's primary endpoint.

$EYPT Just to reiterate in the simplest form: The primary endpoint is the headline grabber and it absolutely matters but the LUGANO story goes well beyond that “miss” DURAVYU delivered across the key secondary endpoints: a 42% reduction in treatment burden, strong supplement-free rates, strong anatomical control, and a favorable safety profile with repeat dosing. That’s why LUCIA matters so much. If LUCIA cleanly hits the primary endpoint while reproducing LUGANO’s secondary results, the overall Phase 3 package could look very different from what the LUGANO headline alone suggests.

$EYPT shorts get ready to buy back shares for me you are getting fucked is more priority than i make profit here. I hate greeds !

$EYPT Watching EYPT drift lower is frustrating, but for those who truly believe in LUCIA, it doesn’t change much. LUCIA remains a binary-risk event, and the outcome will ultimately matter far more than the short-term price action. I don’t have the financial room to add, so I’m just waiting to see how LUCIA plays out. If LUCIA fails, the money invested was at risk anyway. If it succeeds, there’s still plenty of upside. For long-term believers, the current weakness could actually be an opportunity to add at much lower prices.

$EYPT Don't cry like babies calling it scam Everyone knows biopharma stocks carry binary risk wait and watch what it will bring to us. Definitely it will go 6+ hold and wait. The way it's goes down it will rise the same way or may be faster.

$EYPT KOD’s success and current market cap of nearly $6 billion shows the potential value of a successful phase lll Lucia trial results. KOD’s market cap is nearly 20 times our measly $300 plus million market cap. A positive result from the Lucia trial will rocket 🚀 our current price. Extreme potential from here. Fingers crossed.